Literature DB >> 18063703

Purinergic receptors in gastrointestinal inflammation.

Vasantha L Kolachala1, Rahul Bajaj, Meghana Chalasani, Shanthi V Sitaraman.   

Abstract

Purinergic receptors comprise a family of transmembrane receptors that are activated by extracellular nucleosides and nucleotides. The two major classes of purinergic receptors, P1 and P2, are expressed widely in the gastrointestinal tract as well as immune cells. The purinergic receptors serve a variety of functions from acting as neurotransmitters, to autocoid and paracrine signaling, to cell activation and immune response. Nucleosides and nucleotide agonist of purinergic receptors are released by many cell types in response to specific physiological signals, and their levels are increased during inflammation. In the past decade, the advent of genetic knockout mice and the development of highly potent and selective agonists and antagonists for the purinergic receptors have significantly advanced the understanding of purinergic receptor signaling in health and inflammation. In fact, agonist/antagonists of purinergic receptors are emerging as therapeutic modalities to treat intestinal inflammation. In this article, the distribution of the purinergic receptors in the gastrointestinal tract and their physiological and pathophysiological role in intestinal inflammation will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063703     DOI: 10.1152/ajpgi.00454.2007

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  40 in total

1.  A(₂B)AR expression in non-immune cells plays an important role in the development of murine colitis.

Authors:  Sarah A Ingersoll; Hamed Laroui; Vasantha L Kolachala; Lixin Wang; Pallavi Garg; Timothy L Denning; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Dig Liver Dis       Date:  2012-06-19       Impact factor: 4.088

Review 2.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 3.  A(2B) adenosine receptors in immunity and inflammation.

Authors:  György Haskó; Balázs Csóka; Zoltán H Németh; E Sylvester Vizi; Pál Pacher
Journal:  Trends Immunol       Date:  2009-05-07       Impact factor: 16.687

Review 4.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

5.  The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP.

Authors:  Rui Xie; Jingyu Xu; Guorong Wen; Hai Jin; Xuemei Liu; Yuan Yang; Bei Ji; Yixia Jiang; Penghong Song; Hui Dong; Biguang Tuo
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

Review 6.  The role of adenosine signaling in sickle cell therapeutics.

Authors:  Joshua J Field; David G Nathan; Joel Linden
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 7.  Adenosine: an immune modulator of inflammatory bowel diseases.

Authors:  Jeff Huaqing Ye; Vazhaikkurichi M Rajendran
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

8.  Extracellular release of ATP mediated by cyclic mechanical stress leads to mobilization of AA in trabecular meshwork cells.

Authors:  Coralia Luna; Guorong Li; Jianming Qiu; Pratap Challa; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

Review 9.  The roles of purinergic signaling during gastrointestinal inflammation.

Authors:  Jane A Roberts; Mark K Lukewich; Keith A Sharkey; John B Furness; Gary M Mawe; Alan E Lomax
Journal:  Curr Opin Pharmacol       Date:  2012-10-11       Impact factor: 5.547

Review 10.  Differentiating connexin hemichannels and pannexin channels in cellular ATP release.

Authors:  Alexander W Lohman; Brant E Isakson
Journal:  FEBS Lett       Date:  2014-02-15       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.